A clinical trial involving 5045 women in South Africa and Zimbabwe fo...In the context of a comprehensive HIV prevention package provided t...The study to be published online in The Lancet reported an ove...These results do not support the addition of the diaphragm to cu...All participants in the trial received a comprehensive package of s...

A clinical trial involving 5,045 women in South Africa and Zimbabwe found no statistical difference in the rate of new HIV infections in the two study arms: those who received a diaphragm plus lubricant along with male condoms for their partners and those who only received male condoms.

In the context of a comprehensive HIV prevention package provided to all participants, the trial found no additional protective benefit against HIV infection from adding the diaphragm plus lubricant in the intervention arm, said the trials lead investigator, Nancy Padian, PhD, director of UCSFs Womens Global Health Imperative.

The study, to be published online in The Lancet, reported an overall HIV incidence rate of 4.0 percent: 4.1 percent in the intervention arm that included provision of diaphragm and lubricant and 3.9 percent in the control arm that included only provision of condoms. Findings also showed 158 new HIV infections in the intervention arm and 151 in the control group.

These results do not support the addition of the diaphragm to current HIV prevention strategies. Condoms remain the only proven barrier method for HIV prevention, said Padian.

All participants in the trial received a comprehensive package of safer-sex and family planning counseling, free male condoms, diagnosis and treatment of curable sexually transmitted infections, and free contraception.

The investigators could not evaluate whether using the diaphragm alone was better than using nothing, because most women in both arms of the trial reported male condom use.

The trial, known at Methods for Improving Reproductive Health in Africa, or MIRA, began in 2003 and was conducted at sites in Harare, Zimbabwe, and Soweto and Durban, South Africa.

The trial was launched because previous data has suggested that the cells in the cervix are particularly vulnerable to HIV infection, and use of a diaphragm presented the potentia'"/>

(Date:8/1/2015)... ... 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, ... small business donation to kick off the campaign for healing and Well-Being. , BeverlyD ... a complete line of raw, organic hair care products, as well as her book, ...

(Date:7/31/2015)... ... July 31, 2015 , ... That’s ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or ... as well as tried-and-true products that have stood the test of time. These ...

(Date:7/31/2015)... ... , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and ... of Exilis non-surgical fat reduction in New York. Due to its unparalleled level ... clientele. Many patients travel to New York to get their non-surgical skin tightening ...

(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On will ... October 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits ... The West Clinic and The University of Tennessee Health Science Center. A health and ...

... vascular surgeons Clifford Buckley, M.D., and Ruth Bush, M.D., performed ... Conformable GORE TAG Thoracic Endoprosthesis device for the treatment of ... trial. The goal of the trial is to gain ... transection (tear) as a less invasive alternative to major surgery. ...

... National Poll Finds Voters Prefer Tobacco Tax to Other Tax Increases, ... Raising Colorado ,s cigarette tax by $1 ... annual revenue to help close the state,s budget shortfall, while also ... today by a coalition of public health organizations. , (Logo: ...

... National Poll Finds Voters Prefer Tobacco Tax to Other Tax ... Raising Montana ,s cigarette tax by $1 ... new annual revenue to help balance the state,s budget, while also ... today by a coalition of public health organizations. , (Logo: ...

(Date:7/30/2015)... , July 30, 2015 Eisai Inc. ... the United States , European Union ... EMA and MHLW, respectively) for eribulin, for the treatment ... have received prior chemotherapy for advanced or metastatic disease. ... data from a pivotal global Phase 3 clinical trial ...

... Oncobiologics announced today that it has signed two ... early-stage biotech company, and involves worldwide licensing for an ... based large pharmaceutical company to conduct research focused on ... The identity of the client firm was not disclosed ...